Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

Core Insights - SeaStar Medical presented new data on QUELIMMUNE at the ASN Kidney Week 2024, highlighting its cost-saving benefits for treating pediatric acute kidney injury (AKI) [1][2] - QUELIMMUNE demonstrates significant cost neutrality starting at 6 days of therapy, with projected savings of approximately $30,000 per hospitalization compared to standard care [2][3] - The device has shown a high survival rate of 77% in treated children, compared to a control survival rate of around 50% [3] Company Overview - SeaStar Medical is a commercial-stage medical device company focused on reducing hyperinflammation's impact on vital organs through innovative therapies [7] - The Selective Cytopheretic Device (SCD) is a patented technology that targets proinflammatory cells, aiming to improve outcomes in critically ill patients [6] - QUELIMMUNE, the pediatric version of the SCD, received FDA approval in February 2024 under a Humanitarian Device Exemption for use in children with AKI and sepsis [6] Industry Context - Acute Kidney Injury (AKI) poses significant healthcare challenges, often leading to multi-organ dysfunction and increased healthcare costs due to prolonged hospital stays and reliance on dialysis [5] - The ASN Kidney Week is a major event in nephrology, attracting over 12,000 professionals to discuss advancements and challenges in kidney health [4]